发明名称 |
EXPRESSION LEVELS OF BCL-xL, BCL2, BCL-w, AND BAD AND CANCER THERAPIES |
摘要 |
Described herein are novel methods for treating subjects with a cancer which is not overexpressing at least one of BCL-xL, BCL-w, and BAD, and optionally further overexpressing BCL-2. Also provided herein are tools for determining and/or assessing, and for the administration of, cancer treatments involving BET bromodomain inhibitors, BCL-xL inhibitors, or combinations thereof. |
申请公布号 |
EP3125896(A2) |
申请公布日期 |
2017.02.08 |
申请号 |
EP20150717351 |
申请日期 |
2015.04.02 |
申请人 |
Constellation Pharmaceuticals, Inc. |
发明人 |
CONERY, Andrew, Ryan;MERTZ, Jennifer, Andrea;SIMS, Robert, Joseph, III;CENTORE, Richard, C. |
分类号 |
A61K31/517;A61K31/55;A61K31/551;A61K31/5517;A61P35/00 |
主分类号 |
A61K31/517 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|